Patents Examined by Craig D Ricci
  • Three-dimensional self-assembled nucleic acid nanoparticles and use thereof
    Patent number: 11771777
    Abstract: The present invention relates to three-dimensional self-assembled nucleic acid nanoparticles, a drug delivery system comprising the same, and a pharmaceutical composition for the prevention or treatment of acute kidney injury, which comprises the same. The three-dimensional self-assembled nucleic acid nanoparticles of the present invention, which have a tetrahedral structure, exhibit an excellent renal-targeting ability, and thus the nanoparticles conjugated with the pharmaceutically active ingredient for p53 exhibit excellent p53 and caspase 3 expression reductions in vitro and in vivo, and can thereby be applied to the prevention or treatment of acute kidney injury.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: October 3, 2023
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Dae-Ro Ahn, Thai Bao Dieu Hien
  • Non-fused thiophene derivatives and their uses
    Patent number: 11767316
    Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 26, 2023
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Karine Fabienne Malagu, Paul Colin Michael Winship, Jean-Laurent Paparin, Mark Chambers, Jamie David Knight, Roberta Lanaro
  • Steroids and protein-conjugates thereof
    Patent number: 11760775
    Abstract: Described herein are protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: September 19, 2023
    Inventors: Amy Han, Andrew J. Murphy, William Olson
  • Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
    Patent number: 11759464
    Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: September 19, 2023
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Ernest Loumaye, Jean-Pierre Gotteland, Oliver Pohl
  • Methods of treating fibrosis
    Patent number: 11753365
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: September 12, 2023
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Use of succinic acid in increasing sensitivity of bacteria to antibiotics
    Patent number: 11752120
    Abstract: The present invention belongs to the technical field of medicine, and specifically relates to use of succinic acid in increasing sensitivity of bacteria to antibiotics. The present invention found that the succinic acid can increase proton motive force of bacteria, thereby increasing the number of antibiotics entering the bacteria, and eventually killing the bacteria. Therefore, the succinic acid can increase the sensitivity of bacteria to antibiotics, thereby overcoming the problem of bacterial drug resistance. Combining succinic acid with antibiotics can significantly improve the bactericidal effect of the antibiotics, which has better effects and higher safety and operability compared with only using antibiotics as antibacterial drugs at present.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: September 12, 2023
    Assignee: SUN YAT-SEN UNIVERSITY
    Inventors: Hui Li, Bo Peng, Xuanxian Peng
  • Pharmaceutical combinations and methods for the treatment of diabetes and associated disorders
    Patent number: 11738001
    Abstract: The invention relates to pharmaceutical compositions comprising combinations of flavonoids that may be used to treat and/or prevent diabetes and associated diseases, conditions and/or disorders. The invention also relates to methods of treating diabetes and associated diseases, conditions and/or disorders using the pharmaceutical compositions.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: August 29, 2023
    Assignee: OTAGO INNOVATION LIMITED
    Inventors: Philip Myers Heyward, Alexander Tups
  • Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity
    Patent number: 11738043
    Abstract: Disclosed are antiseptic compositions for disinfecting tissues, in particular for ocular use. Methods and compositions disclosed herein include sodium chlorite, optionally in combination with a surfactant.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: August 29, 2023
    Assignee: Allergan, Inc.
    Inventors: James A. Burke, Richard S. Graham, Corine Ghosn, Alexandra Almazan, Michael Engles, Lakshmi Rajagopalan
  • Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
    Patent number: 11733243
    Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: August 22, 2023
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Craig Erickson, Debomoy Lahiri
  • Composition for preventing or improving nociceptive pain
    Patent number: 11730713
    Abstract: Compositions which contain an amino acid comprising serine, and a lipid comprising at least one n-3 fatty acid are useful for preventing or improving nociceptive pain.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: August 22, 2023
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yasuyo Suga, Ikuko Sasahara, Masaki Hashimoto, Tomoyuki Mine, Michihiro Takada, Makoto Ishii, Michiya Kanzaki
  • Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
    Patent number: 11723861
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 15, 2023
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Frank Löscher, Kirsten Eickhoff
  • Selective 5-LO inhibitors for the treatment of bronchial asthma
    Patent number: 11724991
    Abstract: Novel dual 5-LO inhibitors of well validated electrophilic Michael acceptors and nitrogen-heterocycles are presented and designed to maintain specific structural features of currently known dual 5-LO inhibitors and to overcome their drawbacks. The Michael acceptor scaffold will act as a carrier and will provide a stable anchorage via covalent binding to cysteine/histidine residues within the catalytic cleft and/or the surface interface of the 5-LO; whereas, the nitrogen-heterocycles will ensure the access to the Fe(II) catalytic center. These combinations offer potential for more than one mode of iron chelation and 5-LO inhibition.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: August 15, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saadeldin Elsayed Ibrahim Shabaan, Hany Mohamed Abd El-Lateef Ahmed
  • Mirabegron for the treatment of retinal diseases
    Patent number: 11717513
    Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 8, 2023
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Valérie Fontaine, Cécile Vidal, José-Alain Sahel
  • Predictive markers for ATR kinase inhibitors
    Patent number: 11712440
    Abstract: The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: August 1, 2023
    Assignee: Bayer Aktiengesellschaft
    Inventors: Antje Margret Wengner, Gerhard Siemeister, Li Liu
  • Methods of treating heavy menstrual bleeding
    Patent number: 11707464
    Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: July 25, 2023
    Assignee: AbbVie Inc.
    Inventors: Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng
  • C4-carbonothioate-substituted tryptamine derivatives and methods of using
    Patent number: 11707447
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: July 25, 2023
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini
  • Immunomodulator compounds
    Patent number: 11708326
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: July 25, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Christopher Lange, Viengkham Malathong, Venkat Reddy Mali, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Yu Wang, Ju Yang, Penglie Zhang
  • Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
    Patent number: 11696957
    Abstract: The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: July 11, 2023
    Assignee: Sunstate Biosciences, LLC
    Inventor: Changjun Yu
  • Method for the treatment of diseases associated with sulfatase deficiencies
    Patent number: 11696897
    Abstract: A method for a treatment of individuals suffering from diseases associated with sulfatase deficiencies including lysosomal storage disease includes administering at least once a therapeutically effective amount of at least one retinoid. In particular, the compounds tazaroten and bexaroten have beneficial effects on these individuals. Pharmaceutical compositions comprising both active agents namely, tazaroten and bexaroten compounds, or similar compounds, provides for ready treatment of such individuals, and enhanced treatment is achieved with at least two active agents.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: July 11, 2023
    Assignee: GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, UNIVERSITATSMEDIZIN
    Inventors: Lars Schlotawa, Matthias Kettwig, Karthikeyan Radhakrishnan, Thomas Dierks, Jutta Gartner, Matthias Baud
  • Combination therapies with EHMT2 inhibitors
    Patent number: 11672800
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 13, 2023
    Assignee: Epizyme, Inc.
    Inventors: John Emmerson Campbell, Kenneth William Duncan, Maria Alejandra Raimondi, Christine Klaus, Elayne Penebre